Literature DB >> 16856845

cAMP phosphodiesterase-4A1 (PDE4A1) has provided the paradigm for the intracellular targeting of phosphodiesterases, a process that underpins compartmentalized cAMP signalling.

E Huston1, T M Houslay, G S Baillie, M D Houslay.   

Abstract

Specificity of cAMP signalling pathways has shown that the intracellular targeting of the individual components confers a three-dimensional context to the signalling paradigms in which they can exquisitely control the specificity of the outcome of the signal. Pivotal to this paradigm is degradation of cAMP by sequestered PDEs (phosphodiesterases). cAMP rapidly diffuses within cells and, without the action of spatially confined PDE populations, cAMP gradients could not be formed and shaped within cells so as to regulate targeted effector proteins. Of particular importance in regulating compartmentalized cAMP signalling are isoforms of the PDE4 family, which are individually defined by unique N-terminal regions. We have developed and pioneered the concept that a major function of this N-terminal region is to confer intracellular targeting of particular PDE4 isoforms on specific signalling complexes and intracellular locations. The paradigm for this concept developed from our original studies on the PDE4A1 (RD1) isoform. The N-terminal region unique to PDE4A1 consists of two well-defined helical regions separated by a mobile hinge region. Helix-2 provides the core membrane-insertion module, with helix-1 facilitating membrane association and fidelity of targeting in living cells. The irreversible, Ca(2+)-dependent insertion of the N-terminal region of PDE4A1 into membranes provides 'long-term' memory of cell activation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16856845     DOI: 10.1042/BST0340504

Source DB:  PubMed          Journal:  Biochem Soc Trans        ISSN: 0300-5127            Impact factor:   5.407


  13 in total

1.  Targeted inhibition of cyclic AMP phosphodiesterase-4 promotes brain tumor regression.

Authors:  Patricia Goldhoff; Nicole M Warrington; David D Limbrick; Andrew Hope; B Mark Woerner; Erin Jackson; Arie Perry; David Piwnica-Worms; Joshua B Rubin
Journal:  Clin Cancer Res       Date:  2008-12-01       Impact factor: 12.531

2.  Compartmentalization of distinct cAMP signaling pathways in mammalian sperm.

Authors:  Eva Wertheimer; Dario Krapf; José L de la Vega-Beltran; Claudia Sánchez-Cárdenas; Felipe Navarrete; Douglas Haddad; Jessica Escoffier; Ana M Salicioni; Lonny R Levin; Jochen Buck; Jesse Mager; Alberto Darszon; Pablo E Visconti
Journal:  J Biol Chem       Date:  2013-10-15       Impact factor: 5.157

3.  Treating brain tumors with PDE4 inhibitors.

Authors:  Rajarshi Sengupta; Tao Sun; Nicole M Warrington; Joshua B Rubin
Journal:  Trends Pharmacol Sci       Date:  2011-03-28       Impact factor: 14.819

4.  Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1.

Authors:  Nicole M Warrington; Scott M Gianino; Erin Jackson; Patricia Goldhoff; Joel R Garbow; David Piwnica-Worms; David H Gutmann; Joshua B Rubin
Journal:  Cancer Res       Date:  2010-06-15       Impact factor: 12.701

5.  Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis.

Authors:  P H Schafer; A Parton; A K Gandhi; L Capone; M Adams; L Wu; J B Bartlett; M A Loveland; A Gilhar; Y-F Cheung; G S Baillie; M D Houslay; H-W Man; G W Muller; D I Stirling
Journal:  Br J Pharmacol       Date:  2009-12-24       Impact factor: 8.739

6.  Mapping binding sites for the PDE4D5 cAMP-specific phosphodiesterase to the N- and C-domains of beta-arrestin using spot-immobilized peptide arrays.

Authors:  George S Baillie; David R Adams; Narinder Bhari; Thomas M Houslay; Suryakiran Vadrevu; Dong Meng; Xiang Li; Allan Dunlop; Graeme Milligan; Graeme B Bolger; Enno Klussmann; Miles D Houslay
Journal:  Biochem J       Date:  2007-05-15       Impact factor: 3.857

Review 7.  Treating COPD with PDE 4 inhibitors.

Authors:  William M Brown
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2007

8.  Targeting brain tumor cAMP: the case for sex-specific therapeutics.

Authors:  Nicole M Warrington; Tao Sun; Joshua B Rubin
Journal:  Front Pharmacol       Date:  2015-07-28       Impact factor: 5.810

9.  The cAMP phosphodiesterase-4D7 (PDE4D7) is downregulated in androgen-independent prostate cancer cells and mediates proliferation by compartmentalising cAMP at the plasma membrane of VCaP prostate cancer cells.

Authors:  D J P Henderson; A Byrne; K Dulla; G Jenster; R Hoffmann; G S Baillie; M D Houslay
Journal:  Br J Cancer       Date:  2014-02-11       Impact factor: 7.640

10.  Fat storage-inducing transmembrane (FIT or FITM) proteins are related to lipid phosphatase/phosphotransferase enzymes.

Authors:  Matthew Hayes; Vineet Choudhary; Namrata Ojha; John Jh Shin; Gil-Soo Han; George M Carman; Christopher Jr Loewen; William A Prinz; Timothy Levine
Journal:  Microb Cell       Date:  2017-12-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.